<DOC>
	<DOCNO>NCT02073838</DOCNO>
	<brief_summary>This research study ribavirin give combination vismodegib and/or decitabine . The purpose study see patient respond treatment ribavirin give vismodegib alone combination decitabine .</brief_summary>
	<brief_title>Ribavirin Hedgehog Inhibitor With Without Decitabine AML</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>INCLUSION CRITERIA 1 . Patients AML M4 M5 FAB subtype high eIF4E eligible . 2 . All patient must fail primary therapy ( define two induction chemotherapy ) , must relapse , must suitable candidate intensive induction chemotherapy . 3 . Patients dry aspirate extramedullary disease eligible study pretreatment marrow tissue biopsy demonstrate AML M4 M5 subtype high eIF4E . 4 . ECOG performance status 0 , 1 , 2 . 5 . Life expectancy &gt; 4 week . 6 . Age &gt; 18 year . 7 . Female patient childbearing potential ( FCBP ) define sexually mature woman : 1 ) undergone hysterectomy bilateral oophorectomy , 2 ) naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month ) . In addition , woman age 55 year must serum follicle stimulate hormone ( FSH ) level &gt; 40IU/L confirm menopause . FCBP must negative serum ( betaHCG ) pregnancy test ( minimum sensitivity 25 IU/L equivalent unit HCG ) within 7 day start treatment must breastfeed . Men females childbearing potential must agree use two effective mean contraception , one method highly effective method either highly effective less effective list throughout study least 24 month completion protocol . An effective mean contraception include follow : . Male condom spermicide ii . Hormonal method contraception include combined oral contraception pill , vaginal ring , injectables , implant , intrauterine device ( IUDs ) . iii . Nonhormonal IUDs iv . Tubal ligation v. Vasectomy vi . Complete Abstinence A less effective mean contraception include follow : i. Diaphragm spermicide ii . Vaginal sponge iii . Male condom without spermicide iv . Progestin pills female childbearing potential male subject 's FCBP partner v. Female condom ( male female condom must use together ) Male subject must donate semen study 24 month treatment discontinuation . 8 . Adequate renal hepatic function : serum creatinine &lt; 1.5 x ULN ; AST ALT &lt; 2.5 x ULN ( &lt; 5 x ULN liver involvement leukemia ) ; serum bilirubin &lt; 1.5 x ULN 9 . Provide write consent investigational nature , study design , risk benefit study explain . 10 . Accessible treatment follow . EXCLUSION CRITERIA 1 . Patients impaired ribavirin uptake . As tested central laboratory . 2 . Uncontrolled central nervous system involvement AML . 3 . Active cardiovascular disease define New York Heart Association ( NYHA ) class IIIIV categorization . 4 . Patients hemoglobinopathy may affect ability tolerate ribavirin . 5 . Intercurrent illness medical condition preclude safe administration plan protocol treatment require followup . 6 . Received previous therapy AML within 28 day prior study entry . Hydrea permit treatment leukocytosis must stop prior start study drug . 7 . Female patient pregnant breastfeeding . 8 . Concurrent treatment anticancer therapy except adjuvant antihormonal agent breast cancer limit stage prostate cancer . 9 . Known infection HIV . 10 . History active malignancy . Subjects diseasefree 2 year subject history completely resect nonmelanoma skin cancer successfully treat situ carcinoma eligible . 11 . FAB AML M1 , 2 , 6 , 7 exclude high eIF4E expression . AML M3 always exclude .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>